Trevi Therapeutics (TRVI) Projected to Release Quarterly Earnings on Thursday

Trevi Therapeutics (NASDAQ:TRVI) is projected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Trevi Therapeutics to announce earnings of ($0.11) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). On average, analysts expect Trevi Therapeutics to post $-0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Trevi Therapeutics Price Performance

NASDAQ:TRVI opened at $18.09 on Thursday. Trevi Therapeutics has a one year low of $6.55 and a one year high of $20.22. The company has a fifty day moving average price of $16.39 and a 200 day moving average price of $13.66. The stock has a market cap of $2.57 billion, a P/E ratio of -56.53 and a beta of 1.00.

Hedge Funds Weigh In On Trevi Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Kennedy Capital Management LLC lifted its position in shares of Trevi Therapeutics by 2.4% during the 4th quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock worth $704,000 after buying an additional 1,336 shares during the period. California State Teachers Retirement System grew its position in Trevi Therapeutics by 2.6% in the fourth quarter. California State Teachers Retirement System now owns 83,788 shares of the company’s stock valued at $1,049,000 after acquiring an additional 2,091 shares during the period. Rafferty Asset Management LLC raised its stake in Trevi Therapeutics by 21.6% during the fourth quarter. Rafferty Asset Management LLC now owns 16,499 shares of the company’s stock worth $207,000 after acquiring an additional 2,933 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Trevi Therapeutics by 5.3% during the fourth quarter. Russell Investments Group Ltd. now owns 59,444 shares of the company’s stock valued at $744,000 after acquiring an additional 2,984 shares during the period. Finally, Creative Planning boosted its stake in shares of Trevi Therapeutics by 17.5% in the 2nd quarter. Creative Planning now owns 20,247 shares of the company’s stock valued at $111,000 after purchasing an additional 3,016 shares in the last quarter. 95.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. HC Wainwright upped their price objective on shares of Trevi Therapeutics from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Friday, July 17th. Stifel Nicolaus set a $30.00 price objective on Trevi Therapeutics in a report on Friday, May 8th. B. Riley Financial boosted their price objective on Trevi Therapeutics from $21.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Finally, Morgan Stanley restated an “overweight” rating and issued a $20.00 target price on shares of Trevi Therapeutics in a research note on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $24.91.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.